scholarly journals Prognostic and Clinicopathological Value ofPINX1in Various Human Tumors: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10
Author(s):  
Hao Liang ◽  
Zhiyong Xiong ◽  
Ying Li ◽  
Weihao Kong ◽  
Zhicheng Yao ◽  
...  
Keyword(s):  
Malignant Tumors ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Lymphatic Invasion ◽  
Tumor Biomarker ◽  
Tumor Node Metastasis ◽  
Free Survival ◽  
Node Metastasis ◽  
Advanced Tumor ◽  
Tumor Node Metastasis Stage

PINX1(Pin2/TRF1 interacting protein X1, an intrinsic telomerase inhibitor and putative tumor suppressor gene) may represent a novel prognostic tumor biomarker. However, the results of previous studies are inconsistent and the prognostic value ofPINX1remains controversial. Therefore, we conducted a meta-analysis to determine whetherPINX1expression is associated with overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), recurrence-free survival (RFS), and clinicopathological characteristics in patients with malignant tumors. A systematic search was performed in the PubMed, Web of Science, and Embase databases in April 2018. Quality assessment was performed according to the modified Newcastle-Ottawa Scale. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95.0% confidence intervals (CIs) were calculated to determine the relationship betweenPINX1expression and OS, DSS, DFS/RFS, and clinicopathological characteristics. Due to the heterogeneity across the included studies, subgroup and sensitivity analyses were performed. Fixed-effects models were used when the heterogeneity was not significant and random-effects models were used when the heterogeneity was significant. Fourteen studies of 16 cohorts including 2,624 patients were enrolled. LowPINX1expression was associated with poor OS (HR: 1.51, 95.0% CI: 1.03–2.20;P= 0.035) and DFS/RFS (HR: 1.78, 95.0% CI: 1.28–2.47;P= 0.001) but not DSS (HR: 0.80, 95.0% CI: 0.38–1.67;P= 0.548). LowPINX1expression was also associated with lymphatic invasion (OR: 2.23, 95.0% CI: 1.35–3.70;P= 0.002) and advanced tumor-node-metastasis stage (OR: 2.43, 95.0% CI: 1.29–4.57;P= 0.006). No significant associations were observed between lowPINX1expression and sex, depth of invasion, grade of differentiation, and distant metastasis. LowPINX1expression was associated with poor OS and DFS/RFS and lymphatic invasion and advanced tumor-node-metastasis stage, suggesting thatPINX1expression may be a useful predictor of prognosis in patients with malignant tumors.

scholarly journals Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Gastric Cancer: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Ye Qiu ◽  
Zongxin Zhang ◽  
Ying Chen
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Positive Lymph Node ◽  
Node Metastasis ◽  
Advanced Tumor ◽  
Tumor Node Metastasis Stage ◽  
Immune Inflammation

BackgroundPrevious studies have investigated the role of systemic immune-inflammation index (SII) as a prognostic factor for gastric cancer (GC) patients, although with inconsistent results. Thus, the aim of this study was to identify the prognostic value of SII in GC through meta-analysis.MethodsWe systematically searched the PubMed, Embase, and Web of Science databases for relevant studies investigating the prognostic role of SII in GC up to December 2019. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to overall survival (OS) and disease-free survival (DFS) were combined. Odds ratios (ORs) and 95% CIs were pooled to assess the correlation between SII and clinicopathological features of GC.ResultsA total of eight studies, comprising 4,236 patients, were included in this meta-analysis. Pooled analysis indicated that a high pretreatment SII predicted poor OS (HR=1.40, 95% CI=1.08–1.81, p=0.010) but not poor DFS (HR=1.30, 95% CI=0.92–1.83, p=0.140) in GC. In addition, an elevated SII correlated with an advanced tumor–node–metastasis stage (OR=2.34, 95% CI=1.40–3.92, p=0.001), T3–T4 stage (OR=2.25, 95% CI=1.34–3.77, p=0.002), positive lymph node metastasis (OR=1.79, 95% CI=1.12–2.87, p=0.016), and tumor size ≥ 5 cm (OR=2.28, 95% CI=1.62–3.22, p<0.001) in patients with GC.ConclusionsA high pretreatment SII significantly associated with poorer survival outcomes as well as several clinical characteristics in GC. We suggest that SII could be monitored to guide prognostication and provide reliable information on the risk of disease progression in GC.

scholarly journals The prognostic value of p53 positive in colorectal cancer: A retrospective cohort study

Tumor Biology ◽  
2017 ◽  
Vol 39 (5) ◽  
pp. 101042831770365 ◽  
Author(s):  
Peng Wang ◽  
Jianwei Liang ◽  
Zheng Wang ◽  
Huirong Hou ◽  
Lei Shi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Disease Free Survival ◽  
Negative Group ◽  
Tumor Node Metastasis ◽  
Free Survival ◽  
Positive Group ◽  
Node Metastasis ◽  
Tumor Node Metastasis Stage ◽  
Colorectal Cancer Patients ◽  
Disease Free

This retrospective cohort study aimed to discuss the prognostic value of p53 positive in colorectal cancer. A total of 124 consecutive patients diagnosed with colorectal cancer were evaluated at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from 1 January 2009 to 31 December 2010. The expression of p53 in colorectal cancer was examined by immunohistochemistry. Based on the expression levels of p53, the 124 patients were divided into a p53 positive group and a p53 negative group. In this study, 72 patients were in the p53 positive group and 52 in the p53 negative group. The two groups were well balanced in gender, age, body mass index, American Society of Anesthesiologists scores, and number of lymph nodes harvested. p53 positive was associated with carcinoembryonic antigen ≥5 ng/mL ( p = 0.036), gross type ( p = 0.037), degree of tumor differentiation ( p = 0.026), pathological tumor stage ( p = 0.019), pathological node stage ( p = 0.004), pathological tumor–node–metastasis stage ( p = 0.017), nerve invasion ( p = 0.008), and vessel invasion ( p = 0.018). Tumor site, tumor size, and pathological pattern were not significantly different between these two groups. Disease-free survival and overall survival in the p53 positive group were significantly shorter than the p53 negative group ( p = 0.021 and 0.025, respectively). Colorectal cancer patients with p53 positive tended to be related to a higher degree of malignancy, advanced tumor–node–metastasis stage, and shorter disease-free survival and overall survival. p53 positive was independently an unfavorable prognostic marker for colorectal cancer patients.

Circulating serum exosomal miR-92a-3p as a novel biomarker for early diagnosis of gastric cancer

2021 ◽  
Vol 17 (8) ◽  
pp. 907-919
Author(s):  
Xu Lu ◽  
Jianxin Lu ◽  
Siqi Wang ◽  
Yu Zhang ◽  
Ye Ding ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Diagnosis ◽  
Malignant Tumors ◽  
Area Under The Curve ◽  
Tumor Biomarker ◽  
Diagnostic Efficiency ◽  
Node Metastasis ◽  
Tumor Node Metastasis Stage ◽  
Combined Detection ◽  
Serum Exosomes

Gastric cancer (GC) is one of the common malignant tumors with high mortality. The abundance of miRNAs in serum exosomes has proved to have a high application value as a new noninvasive diagnostic method. The purpose of this study was to investigate whether serum exosomal miR-92a-3p could be used as a new biomarker for early diagnosis of GC and evaluate its clinical application value by detecting the expression of serum exosomal miR-92a-3p in 131 patients with primary GC and 122 healthy controls by real-time quantitative (qRT)-PCR. The results showed that the expression level of serum exosomal miR-92a-3p in GC patients was significantly lower than that in normal controls (p < 0.0001). In addition, the level was closely correlated with lymph node metastasis and tumor node metastasis stage of GC patients. The area under the curve for serum exosomal miR-92a-3p was 0.829, significantly higher than for other indicators. Furthermore, combined detection of serum exosomal miR-92a-3p, CEA and CA19-9 was more sensitive than any of the three alone or any pair. These results showed that serum exosomal miR-92a-3p could be used as a novel new tumor biomarker to improve diagnostic efficiency in GC.

scholarly journals Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tian Fang ◽  
Tingting Liang ◽  
Yizhuo Wang ◽  
Haitao Wu ◽  
Shuhan Liu ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Gene Mutation ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Features ◽  
Mutation Status ◽  
Free Survival ◽  
Node Metastasis ◽  
Viral Oncogene Homolog

Abstract Background Approximately 5.0–24.2% of colorectal cancers (CRCs) have inactivating mutations in SMAD4, making it one of the frequently mutated genes in CRC. We thus carried out a comprehensive system review and meta-analysis investigating the prognostic significance and clinicopathological features of SMAD4 gene mutation in CRC patients. Methods A detailed literature search was conducted in PubMed, Web of Science and Embase databases to study the relationship between SMAD4 mutations and the demographic and clinicopathological characteristics in CRC patients. The hazard ratios (HRs) with 95% confidence intervals (CI) were used to evaluate the effect of SMAD4 mutations on overall survival (OS) and progression-free survival (PFS)/recurrence-free survival (RFS). Results Ten studies enrolling 4394 patients were eligible for inclusion. Data on OS were available from 5 studies and data on PFS/RFS were available from 3 studies. Comparing SMAD4-mutated CRC patients with SMAD4 wild-type CRC patients, the summary HR for OS was 1.46 (95% CI 1.28–1.67, P = 0.001), the summary HR for PFS/RFS was 1.59 (95% CI 1.14–2.22, P = 0.006). In terms of clinicopathology parameters, 9 studies have data that can be extracted, SMAD4 mutations were associated with tumor location (odds ratio [OR] = 1.15, colon/rectum, 95% CI 1.01–1.31, P = 0.042), TNM stage (OR = 1.28, stage IV/I–III, 95% CI 1.03–1.58, P = 0.025), lymph node metastasis (OR = 1.42, N1 + N2/N0, 95% CI 1.20–1.67, P < 0.001), mucinous differentiation (OR = 2.23, 95% CI 1.85–2.70, P < 0.001) and rat sarcoma viral oncogene homolog (RAS) mutation status (OR = 2.13, 95% CI 1.37–3.34, P = 0.001). No connection was found with age, gender, tumor grade, microsatellite instability status and b-viral oncogene homolog B1 mutation status. Besides, publication bias was not observed in any study. Conclusions This meta-analysis suggests that SMAD4 mutation was associated with OS, PFS/RFS, and clinicopathological parameters, including tumor site, disease stage, RAS status, lymph node metastasis and mucinous differentiation. Our meta-analysis indicated that SMAD4 mutations could predict the poor prognosis and aggressive clinicopathological characteristics of CRC. More large-sample cohort studies are needed to confirm this conclusion. Since SMAD4 mutations are closely related to RAS mutations, their relationship warrants further investigation.

scholarly journals High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Miao Zhang ◽  
Xuan-zhang Huang ◽  
Yong-xi Song ◽  
Peng Gao ◽  
Jing-xu Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Clinicopathological Characteristics ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Node Negative ◽  
Lymphocyte Ratio

Background. We aimed to evaluate the correlation of platelet-to-lymphocyte ratio (PLR) with prognosis and clinicopathological characteristics of breast cancer. Methods. The PubMed and Embase databases were searched. Hazard ratio (HR) with 95% confidence interval (CI) was used to summarize disease-free survival (DFS) and overall survival (OS). Odds ratio (OR) was used to summarize tumor clinicopathological characteristics. Results. High PLR was associated with poor DFS and OS (DFS: HR = 1.47, 95% CI = 1.16–1.85, and Tau2 = 0.070; OS: HR = 1.88, 95% CI = 1.27–2.80, and Tau2 = 0.192). A Galbraith plot indicated that the studies by Allan et al. and Cihan et al. contributed the heterogeneity of DFS and OS, respectively. There were significant differences in the incidence of high PLR between stage II–IV and stage I groups (OR = 1.86, 95% CI = 1.20–2.90, and Tau2 < 0.001), between lymph node-positive and lymph node-negative groups (OR = 1.52, 95% CI = 1.22–1.91, and Tau2 =0.014), and between metastasis-positive and metastasis-negative groups (OR = 4.24, 95% CI = 2.73–6.59, and Tau2 < 0.001). Conclusions. Our results indicated that PLR was associated with poor prognosis of breast cancer and adequately predicted clinicopathological characteristics.

scholarly journals WNT5A Correlates with Clinicopathological Characteristics in Gastric Cancer: a Meta-Analysis

2017 ◽  
Vol 41 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Seungyoon Nam ◽  
Jun-Won Chung ◽  
Jun-Young Yang
Keyword(s):  
Gastric Cancer ◽  
Wnt Signaling ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Cochrane Library ◽  
Systematic Analysis ◽  
Advanced Tumor ◽  
Advanced Stages ◽  
Cancer Types ◽  
Embryonic Signaling

Background/Aims: Gastric cancer (GC), the third-leading cause of cancer death in the world, is typically diagnosed only in its advanced stages. WNT signaling has been associated with clinicopathological characteristics in diverse cancer types. But the systematic analysis of WNT5A, a member in the signaling, has not been inspected. Thus, our study used a meta-analysis to statistically associate WNT5A expression with GC clinicopathological characteristics. Methods: For a systematic literature review of GC in combination with the WNT signaling molecule WNT5A, we searched for PubMed, Cochrane Library, and Web of Science. It led to the five cohorts, in four eligible studies, consisting of 1,034 patients (617 WNT5A-positive and 417 WNT5A-negative patients). These patients were inspected by the library “meta” in R software for our meta-analysis. Results: Our meta-analysis, revealed a statistically significant associations of WNT5A-positivity with lymph node metastasis (p=0.0047), some types of Lauren diffuse subtype GCs (p<0.0001), advanced tumor depth (p<0.0001), and advanced UICC stages (p=0.0461) with no observation of bias or confounding factors. Conclusions: These results support the feasibility of targeting this embryonic signaling pathway, both for therapy, and as a biomarker to “guide” various individual interventions (i.e., “personalized medicine”).

Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer

2000 ◽  
Vol 18 (20) ◽  
pp. 3529-3534 ◽  
Author(s):  
Paulo M. Hoff ◽  
Nora Janjan ◽  
Everardo D. Saad ◽  
John Skibber ◽  
Christopher Crane ◽  
...  
Keyword(s):  
Progressive Disease ◽  
Combined Modality Therapy ◽  
Sphincter Preservation ◽  
Preoperative Radiation ◽  
Tumor Node Metastasis ◽  
Node Metastasis ◽  
Pathologic Evaluation ◽  
Tumor Node Metastasis Stage ◽  
Days Of Therapy ◽  
Dose Limiting Toxicity

PURPOSE: Preoperative combined-modality therapy for rectal cancermay allow for sphincter preservation, while decreasing recurrencerates and improving the overall prognosis. Oral chemotherapy withuracil and tegafur (UFT) plus leucovorin (LV) may reduce costs andcomplications associated with protracted infusions offluorouracil. Our goal was to evaluate the safety of UFT plus LVcombined with preoperative radiation and determine themaximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of UFTplus LV in this setting. PATIENTS AND METHODS: Patients with tumor-node-metastasis stage II or III rectalcancer received escalating doses of UFT (starting at 250mg/m2/d, with50-mg/m2/d increments between consecutivecohorts) and fixed doses of LV (90 mg/d). The UFT and LV combinationwas given 5 days per week concurrently with a 5-week course ofpreoperative radiation totaling 45 Gy (1.8 Gy/fraction). Surgery wasperformed 4 to 6 weeks after radiation and was followed by four 35-daycycles of fixed doses of UFT and LV (28 days of therapy eachcycle). RESULTS: Fifteen patients weretreated, and 13 received the full preoperative chemotherapy. Allplanned radiation was delivered successfully. The MTD of UFT withradiation was 350 mg/m2/d with 90 mg/d ofLV. Diarrhea was the DLT. Sphincter-preserving surgery was performedin 12 of 14 patients. One patient had progressive disease beforesurgery. Pathologic evaluation of 14 resected specimens showed acomplete response in three cases. CONCLUSION: Preoperative chemoradiation with oral UFT plus LV isfeasible and well tolerated and should be furtherinvestigated.

scholarly journals Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9675
Author(s):  
Huijuan Wang ◽  
Pingping Wang ◽  
Yu Wu ◽  
Xiukun Hou ◽  
Zechun Peng ◽  
...  
Keyword(s):  
Clinicopathological Characteristics ◽  
Normal Weight ◽  
Obese Group ◽  
Papillary Thyroid ◽  
Weight Group ◽  
Normal Weight Group ◽  
Advanced Tumor ◽  
Tumor Node Metastasis Stage ◽  
Overweight Group ◽  
The Relationship

Objective To explore the relationship between body mass index (BMI) and clinicopathological characteristics in patients with papillary thyroid carcinoma (PTC). Methods The clinical data of 1,579 patients with PTC, admitted to our hospital from May 2016 to March 2017, were retrospectively analyzed. According to the different BMI of patients, it can be divided into underweight recombination (BMI < 18.5 kg/m), normal body recombination (18.5 ≤ BMI < 24.0 kg/m2), overweight recombination (24.0 ≤ BMI < 28.0 kg/m2) and obesity group (BMI ≥ 28.0 kg/m2). The clinicopathological characteristics of PTC in patients with different BMIs group were compared. Results In our study, the risk for extrathyroidal extension (ETE), advanced T stage (T III/IV), and advanced tumor-node-metastasis stage (TNM III/IV) in the overweight group were higher, with OR (odds ratio) = 1.99(1.41–2.81), OR = 2.01(1.43–2.84), OR = 2.94(1.42–6.07), respectively, relative to the normal weight group. The risk for ETE and T III/IV stage in the obese group were higher, with OR = 1.82(1.23–2.71) and OR = 1.82(1.23–2.70), respectively, relative to the normal weight group. Conclusion BMI is associated with the invasiveness of PTC. There is a higher risk for ETE and TNM III/IV stage among patients with PTC in the overweight group and for ETE among patients with PTC in the obese group.

KRT 15 as a prognostic biomarker is highly expressed in esophageal carcinoma

2020 ◽  
Vol 16 (25) ◽  
pp. 1903-1909
Author(s):  
Jian-bo Lin ◽  
Zhi Feng ◽  
Ming-lian Qiu ◽  
Rong-gang Luo ◽  
Xu Li ◽  
...  
Keyword(s):  
Western Blot ◽  
Esophageal Carcinoma ◽  
Prognostic Biomarker ◽  
High Expression ◽  
Tumor Node Metastasis ◽  
Expression Levels ◽  
Normal Tissues ◽  
Node Metastasis ◽  
Tumor Node Metastasis Stage ◽  
Expression Rate

Aim: To investigate the expression and prognostic value of KRT 15 in esophageal carcinoma. Materials & methods: The expression levels of KRT 15 were measured in 128 cases of esophageal carcinoma and matched adjacent normal tissues by immunohistochemistry and Western blot assays. Results & conclusion: Western blot analysis shown the expression levels of KRT 15 in esophageal carcinoma were significantly higher compared with those in matched adjacent normal tissues (p < 0.001). immunohistochemistry result shown the high-expression rate of KRT 15 in esophageal carcinoma were 56.3%, which was significantly higher than those in normal tissues (35.9%; p = 0.002). KRT 15 high-expression correlated with T stage, lymph node metastasis, tumor node metastasis stage and prognosis (p < 0.05). These data indicate KRT 15 as a prognostic biomarker is highly expressed in esophageal carcinoma.

Sign in / Sign up

Export Citation Format

Share Document